https://scholar.dgist.ac.kr/handle/20.500.11750/6319 Sat, 04 Apr 2026 21:12:17 GMT 2026-04-04T21:12:17Z https://scholar.dgist.ac.kr/handle/20.500.11750/59044 Title: COMPOSITION FOR TREATING ALZHEIMER`S DISEASE COMPRISING AS ACTIVE INGREDIENT MIXED EXTRACT OF PINELLIA TERNATA BREITENBACH, ZIZYPHUS JUJUBA VAR. INERMIS REHDER, GLYCYRRHIZA URALENSIS FISCHER, PANAX GINSENG, ZINGIBER OFFICINALE ROSCOE, SCUTELLARIA BAICALENSIS, AND COPTIS RHIZOME Author(s): 김재광; 박여진; 서진수; 최장기; 김부윤; 박맑은; 오태우; 고영훈; 이혜인 Abstract: The present invention relates to use of a composition comprising Banhasasim-tang as an active ingredient for the treatment, amelioration or prevention of Alzheimer's disease caused by ApoE4 genetic variation. The composition comprising Banhasasim-tang as an active ingredient and a treatment method, according to the present invention, exhibit excellent effects of reducing amyloid beta protein and inhibiting the precipitation thereof in a manner specific to Alzheimer's disease caused by ApoE4 genetic variation, and thus are greatly used as a preventive, ameliorating or therapeutic composition specific to Alzheimer's disease caused by ApoE4 genetic variation. https://scholar.dgist.ac.kr/handle/20.500.11750/59044 https://scholar.dgist.ac.kr/handle/20.500.11750/59042 Title: METHOD FOR DIAGNOSING ALZHEIMER`S DISEASE BY USING ANKS1A PROTEIN VARIANT OR POLYNUCLEOTIDE ENCODING SAME Author(s): 서진수; 박선아; 박수철 Abstract: An ANKS1A-A355D protein variant is found in Alzheimer's disease patients, and unlike a normal ANKS1A protein, is unable to induce the cell membrane expression of an LRP1 receptor, and thus is unable to efficiently remove toxic proteins such as an amyloid beta peptide. Therefore, provided is a method for providing early diagnosis information on the onset of Alzheimer's disease by confirming the expression level of an ANKS1A-A355D protein variant or detecting the presence or absence of a gene encoding the ANKS1A-A355D protein variant. Also, provided is a composition comprising an agent for detecting an ANKS1A-A355D protein variant or a polynucleotide encoding same. https://scholar.dgist.ac.kr/handle/20.500.11750/59042 https://scholar.dgist.ac.kr/handle/20.500.11750/58829 Title: Composition for treating alzheimer's disease comprising mixed extract of pinellia ternate, jujube, liquorice, ginseng, rhizoma zingiberis, scutellaria baicalensis and coptis chinensis as active ingredient Author(s): 서진수; 고영훈; 김재광; 박맑은; 이혜인; 최장기; 박여진; 오태우; 김부윤 Abstract: The invention relates to a composition for treating, improving or preventing Alzheimer's disease caused by ApoE4 gene mutation. The composition comprises pinellia ternate heart-fire purging decoction as an active ingredient. The composition containing the pinellia ternate heart-fire purging decoction as an active ingredient and the treatment method show excellent effects of reducing beta amyloid protein (which is specific to Alzheimer's disease caused by ApoE4 gene mutation) and inhibiting deposition of the beta amyloid protein; thus, the composition has high applicability as a specific composition for preventing, ameliorating or treating Alzheimer's disease caused by ApoE4 gene mutation. https://scholar.dgist.ac.kr/handle/20.500.11750/58829 https://scholar.dgist.ac.kr/handle/20.500.11750/58786 Title: ALZHEIMER-RESISTANT CELL MODEL INCLUDING APOE CHRISTCHURCH MUTATION AND CONSTRUCTION METHOD THEREFOR Author(s): 조준호; 이혜인; 서진수; 장금미; 배심성 Abstract: The present invention relates to an Alzheimer-resistant human pluripotent stem cell model having an ApoE Christchurch mutation inserted thereinto and a construction method therefor and, more specifically, to an Alzheimer-resistant human induced pluripotent stem cell model and brain cell/brain organoid into which an ApoE Christchurch mutation is inserted using a CRISPR/Cas9 system, and a construction method therefor. According to the present invention, Alzheimer-resistant human induced pluripotent stem cells and a brain cell/brain organoid are constructed by inserting an ApoE Christchurch mutation into human induced pluripotent stem cells with the aid of a CRISPR/Cas9 gene editing technique and as such, can surmount the limitations observed in preexisting animal models, such as protein expression patterns different from those in human cells, etc. The Alzheimer-resistant cell model of the present invention can find advantageous applications in research into ApoE-associated Alzheimer pathogenesis, etc. https://scholar.dgist.ac.kr/handle/20.500.11750/58786